Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 63

Results For "2023"

1090 News Found

Hikal posts Q1 FY 24 consolidated PAT at Rs. 6.92 Cr
News | August 09, 2023

Hikal posts Q1 FY 24 consolidated PAT at Rs. 6.92 Cr

US FDA approval is in line with de-risking strategy for additional API site to service our global customer base


Lonza launches nebula absorbance reader for streamlined Endotoxin and Pyrogen testing
Digitisation | August 09, 2023

Lonza launches nebula absorbance reader for streamlined Endotoxin and Pyrogen testing

The instrument is fully integrated with Lonza’s latest WinKQCLSoftware to enable data integrity compliance, streamline training, and reduce validation burden


Mandaviya addresses BRICS Health Minister’s meeting
News | August 09, 2023

Mandaviya addresses BRICS Health Minister’s meeting

Reiterates India’s commitment to the BRICS TB Research Network Initiative


USFDA completes PAD E inspection of Marksans' Goa facility
Drug Approval | August 09, 2023

USFDA completes PAD E inspection of Marksans' Goa facility

The inspection was conducted at its Goa, Vema manufacturing facility


KIMS posts Q1 FY24 consolidated PAT at Rs. 80.81 Cr
News | August 08, 2023

KIMS posts Q1 FY24 consolidated PAT at Rs. 80.81 Cr

KIMS has reported total income of Rs. 609.14 crores during the period ended June 30, 2023


Torrent Pharmaceuticals posts Q1 FY 24 consolidated PAT at Rs. 378 Cr
News | August 08, 2023

Torrent Pharmaceuticals posts Q1 FY 24 consolidated PAT at Rs. 378 Cr

Torrent Pharmaceuticals has reported total income of Rs. 2625 crores during the period ended June 30, 2023


Gland Pharma posts Q1 FY24 consolidated PAT at Rs. 194.10 Cr
News | August 08, 2023

Gland Pharma posts Q1 FY24 consolidated PAT at Rs. 194.10 Cr

Gland Pharma has reported total income of Rs. 1246.23 crores during the period ended June 30, 2023


Tatva Chintan Pharma Chem posts Q1 FY24 consolidated PAT at Rs. 9.50 Cr
News | August 06, 2023

Tatva Chintan Pharma Chem posts Q1 FY24 consolidated PAT at Rs. 9.50 Cr

The company has reported total income of Rs. 115.37 crores during the period ended June 30, 2023


Eugia Pharma receives USFDA approval for Vancomycin Hydrochloride for Injection USP
Drug Approval | August 06, 2023

Eugia Pharma receives USFDA approval for Vancomycin Hydrochloride for Injection USP

The product is being launched in August 2023